Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Partner Samsung Bioepis Settles On Stelara In US

Partners Snag Third-Earliest Launch Date So Far For Biosimilar Ustekinumab

Executive Summary

Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.

You may also be interested in...



A $10bn Target: Stelara Sales Break Barrier Ahead Of Biosimilar Launches

With competition to Stelara due to kick in midway through 2024, the brand now represents a $10bn+ target for biosimilars, according to the latest figures from J&J.

Another Stelara Settlement Revealed As Accord Files US Biosimilar

A further US settlement agreement over Stelara has been struck with originator Janssen, with Accord BioPharma revealing the deal at the same time as it announced that a filing for its Dong-A/Meiji Seika-partnered DMB-3115 biosimilar ustekinumab candidate had been accepted for review by the FDA.

A Year Of Change: Sandoz Completes A Transformational 2023

An eventful 2023 for Sandoz saw multiple major deals and key launches, with the year culminating in the firm’s long-awaited spinoff from parent company Novartis in October.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel